*Melanoma Institute Australia
‡Central Clinical School, The University of Sydney, Sydney
†Royal Prince Alfred Hospital Camperdown, NSW, Australia
§Departments of Surgical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston TX
Conflicts of Interest and Source of Funding: J.F.T. has been a member of advisory boards for and received honoraria/travel support from GlaxoSmithKline, Merck Sharp Dohme, Bristol Myers Squibb and Provectus Inc., all unrelated to the content of this work. J.F.T. is supported by the Melanoma Foundation of the University of Sydney. J.E.G. has served in a consultant or advisory role for Merck, Bristol-Myers Squibb, Novartis, Syndax, Neracare, and Castle Biosciences, unrelated to the content of this work. R.A.S. has served on advisory boards for Merck Sharp Dohme, Novartis, Myriad and NeraCare, unrelated to the content of this work. R.A.S. is supported by the National Health and Medical Research Council.